The retrograde trafficking of EGFR towards the nucleus was a tumor-specific event that could be driven by the association with MUC1 or a loss of polarity, and these data prompted us to evaluate targeting this pathway therapeutically [18, 36, 37]. The gene discussed is MUC1; the disease is neoplasm.